Chimera is under intense pressure from the current macroeconomic environment. Read more to see why the preferreds (CIM.PB) offer a safer way to gain exposure.Read full newsRead More
Progress Software is acquiring on-premise NoSQL database vendor MarkLogic for $355m. Learn more about the deal and my recommendation.Read full newsRead More
Warren Buffett's Berkshire Hathaway bought an over $4 billion stake in TSMC in Q3, 2022. Find out why I rate TSM stock a strong buy.Read full newsRead More
Amazon seems finally ready to enter a formal film strategy centered on the multiplex first-window. This is an important development in becoming a true media conglomerate.Read full newsRead More
We like boring businesses that are essential in all market conditions. Find out 2 dividend-growing picks yielding up to 8% to build your income in this bear market.Read full newsRead More
By yield, ZIM leads the top-ten All-Star-Value field of CTRA, ORCC, PXD, KEN, PBR, ICL, HIMX, AKO.B, LPG, and ZIM. Click here to read more.Read full newsRead More
Alleima (SAMHF) will be debt free and has pledged to pay 50% of its normalized net income as a dividend. Find out why I'm bullish on the stock.Read full newsRead More
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. Pros and cons to owning his top 5 stocks.Read full newsRead More
Golden Ocean's stellar dividend yield of 13.8% should not be ignored. See why we continue to rate GOGL stock as a Buy.Read full newsRead More
Following a promising rally in October FY22, Inhibrx failed to break to new highs. Read more to see my technical analysis on INBX and my fair value price range.Read full newsRead More
UTG yields 7.92% and pays monthly and its total return outperformed S&P over the past year and most recent trading quarter. See why I rate the fund a buy.Read full newsRead More
EOG Resources success is based on its operational excellence. See why EOG stock represents a compelling investment for long-term focused investors.Read full newsRead More
US equity markets rallied on the first week of the year after employment data showed strong job growth. Learn more about real estate weekly outlook.Read full newsRead More
With underlying business momentum cooling off, MKS Instruments is not out of the woods yet. Click here for a full investment analysis of MKSI stock.Read full newsRead More
Immunovant is developing a similar drug to argenx, but at 10% of argenx's valuation. Read more to see the growth catalysts, risks and why I consider IMVT stock a buy now.Read full newsRead More
Meta is undervalued regardless of the Metaverse results. Find out why we recommend buying META stock at this level.Read full newsRead More
Warren Buffett's investment in Paramount Global hasn't been enough to stanch the decline in its stock. Click here to read our latest analysis on PARA stock.Read full newsRead More
Hamilton Lane is trading at a premium to the industry average. Read more to see why we think HLNE's premium is not justified.Read full newsRead More
Bristol-Myers Squibb is a high quality business that's currently on sale. See why I find BMY stock to be a Buy for potentially strong long-term returns.Read full newsRead More
The Coca-Cola Company is a Dividend King with a streak of 60 years of increases. Click here to read my analysis of KO stock.Read full newsRead More